|
|
Blood, 1 November 2004, Vol. 104, No. 9, pp. 2967-2975.
Prepublished online as a Blood First Edition Paper on July 13, 2004; DOI 10.1182/blood-2004-05-1866.
 Previous Article | Table of Contents | Next Article 
RED CELLS
Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation
Nghia T.V. Le, and
Des R. Richardson
From the Children's Cancer Institute Australia for Medical Research, Iron Metabolism and Chelation Program, Sydney, Australia.
Iron (Fe) is critical for proliferation, but its precise role in cell cycle progression remains unclear. In this study, we examined the mechanisms involved by assessing the effects of Fe chelators on the expression of molecules that play key roles in this process. In initial studies, gene arrays were used to assess gene expression after incubating cells with 2 Fe chelators, namely, desferrioxamine (DFO) and 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (311), or the DNA-damaging agent, actinomycin D. From the genes assessed, only the N-myc downstream-regulated gene 1 (Ndrg1) was specifically up-regulated by Fe chelation. Although the function of Ndrg1 is unclear, previous studies showed it markedly slows tumor growth and acts as a potent metastasis suppressor. Incubation of cells with chelators markedly increased Ndrg1 mRNA and protein expression, but this was not found with their Fe complexes or when the Fe-binding site had been inactivated. Increased Ndrg1 expression following Fe chelation was related to the permeability and antiproliferative activity of chelators and could be reversed by Fe repletion. Moreover, Ndrg1 up-regulation after chelation occurred at the transcriptional level and was mediated by hypoxia inducible factor-1 (HIF-1)-dependent and -independent mechanisms. Our investigation suggests Ndrg1 is a novel link between Fe metabolism and the control of proliferation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Iron and cell proliferation: another piece of the puzzle
- Prem Ponka
Blood 2004 104: 2620-2621.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
K.-H. Zhang, H.-Y. Tian, X. Gao, W.-W. Lei, Y. Hu, D.-M. Wang, X.-C. Pan, M.-L. Yu, G.-J. Xu, F.-K. Zhao, et al.
Ferritin Heavy Chain-Mediated Iron Homeostasis and Subsequent Increased Reactive Oxygen Species Production Are Essential for Epithelial-Mesenchymal Transition
Cancer Res.,
July 1, 2009;
69(13):
5340 - 5348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Peslova, J. Petrak, K. Kuzelova, I. Hrdy, P. Halada, P. W. Kuchel, S. Soe-Lin, P. Ponka, R. Sutak, E. Becker, et al.
Hepcidin, the hormone of iron metabolism, is bound specifically to {alpha}-2-macroglobulin in blood
Blood,
June 11, 2009;
113(24):
6225 - 6236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Assinder, Q. Dong, H. Mangs, and D. R. Richardson
Pharmacological Targeting of the Integrated Protein Kinase B, Phosphatase and Tensin Homolog Deleted on Chromosome 10, and Transforming Growth Factor-{beta} Pathways in Prostate Cancer
Mol. Pharmacol.,
March 1, 2009;
75(3):
429 - 436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Zacharski, B. K. Chow, P. S. Howes, G. Shamayeva, J. A. Baron, R. L. Dalman, D. J. Malenka, C. K. Ozaki, and P. W. Lavori
Decreased Cancer Risk After Iron Reduction in Patients With Peripheral Arterial Disease: Results From a Randomized Trial
J Natl Cancer Inst,
July 16, 2008;
100(14):
996 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Whitnall, Y. S. Rahmanto, R. Sutak, X. Xu, E. M. Becker, M. R. Mikhael, P. Ponka, and D. R. Richardson
The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation
PNAS,
July 15, 2008;
105(28):
9757 - 9762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Narbonne-Reveau, S. Senger, M. Pal, A. Herr, H. E. Richardson, M. Asano, P. Deak, and M. A. Lilly
APC/CFzr/Cdh1 promotes cell cycle progression during the Drosophila endocycle
Development,
April 15, 2008;
135(8):
1451 - 1461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Xu, R. Sutak, and D. R. Richardson
Iron Chelation by Clinically Relevant Anthracyclines: Alteration in Expression of Iron-Regulated Genes and Atypical Changes in Intracellular Iron Distribution and Trafficking
Mol. Pharmacol.,
March 1, 2008;
73(3):
833 - 844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Boult, K. Roberts, M. J. Brookes, S. Hughes, J. P. Bury, S. S. Cross, G. J. Anderson, R. Spychal, T. Iqbal, and C. Tselepis
Overexpression of Cellular Iron Import Proteins Is Associated with Malignant Progression of Esophageal Adenocarcinoma
Clin. Cancer Res.,
January 15, 2008;
14(2):
379 - 387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Ellen, Q. Ke, P. Zhang, and M. Costa
NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states
Carcinogenesis,
January 1, 2008;
29(1):
2 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Zhang, K.-M. Tchou-Wong, and M. Costa
Egr-1 Mediates Hypoxia-Inducible Transcription of the NDRG1 Gene through an Overlapping Egr-1/Sp1 Binding Site in the Promoter
Cancer Res.,
October 1, 2007;
67(19):
9125 - 9133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hershko
Cell-cycle regulation by iron depletion
Blood,
July 15, 2007;
110(2):
474 - 475.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fu and D. R. Richardson
Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion
Blood,
July 15, 2007;
110(2):
752 - 761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Nurtjahja-Tjendraputra, D. Fu, J. M. Phang, and D. R. Richardson
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression
Blood,
May 1, 2007;
109(9):
4045 - 4054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. I. Haurani
Hepcidin and the anemia of chronic disease.
Ann. Clin. Lab. Sci.,
December 1, 2006;
36(1):
3 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sterba, O. Popelova, T. Simunek, Y. Mazurova, A. Potacova, M. Adamcova, H. Kaiserova, P. Ponka, and V. Gersl
Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity
J. Pharmacol. Exp. Ther.,
December 1, 2006;
319(3):
1336 - 1347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Kovacevic and D. R. Richardson
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer
Carcinogenesis,
December 1, 2006;
27(12):
2355 - 2366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson
Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond
Clin. Cancer Res.,
December 1, 2006;
12(23):
6876 - 6883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.L. Dunn, E.O. Sekyere, Y. Suryo Rahmanto, and D.R. Richardson
The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis
Carcinogenesis,
November 1, 2006;
27(11):
2157 - 2169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Whitnall, J. Howard, P. Ponka, and D. R. Richardson
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
PNAS,
October 3, 2006;
103(40):
14901 - 14906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Jones and A. L. Harris
Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding.
Mol. Cancer Ther.,
September 1, 2006;
5(9):
2193 - 2202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Maruyama, M. Ono, A. Kawahara, T. Yokoyama, Y. Basaki, M. Kage, S. Aoyagi, H. Kinoshita, and M. Kuwano
Tumor Growth Suppression in Pancreatic Cancer by a Putative Metastasis Suppressor Gene Cap43/NDRG1/Drg-1 through Modulation of Angiogenesis.
Cancer Res.,
June 15, 2006;
66(12):
6233 - 6242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. Davies, Y. S. Rahmanto, C. R. Chitambar, and D. R. Richardson
Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates
J. Pharmacol. Exp. Ther.,
April 1, 2006;
317(1):
153 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. O. Sekyere, L. L. Dunn, Y. S. Rahmanto, and D. R. Richardson
Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo
Blood,
April 1, 2006;
107(7):
2599 - 2601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Jones, I. S. Trowbridge, and A. L. Harris
Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate.
Cancer Res.,
March 1, 2006;
66(5):
2749 - 2756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Kalinowski and D. R. Richardson
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Pharmacol. Rev.,
December 1, 2005;
57(4):
547 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Holtz, S. J. Forman, and R. Bhatia
Pre-Stimulation of CML CD34+ Cells with High Concentrations of Growth Factors Counters Imatinib-Mediated Proliferation Suppression and Enhances Apoptosis of Non-Dividing Cells.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
2479 - 2479.
[Abstract]
|
|
|
|
|
|
|
H. Y. Yeung, K. P. Lai, H. Y. Chan, N. K. Mak, G. F. Wagner, and C. K. C. Wong
Hypoxia-Inducible Factor-1-Mediated Activation of Stanniocalcin-1 in Human Cancer Cells
Endocrinology,
November 1, 2005;
146(11):
4951 - 4960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
